Join the Oncology Voice Network. Join for Free
The Value of In-House Medical Affairs to the MSL E205 • May 14, 2024 • 29 mins
MSLs in-house medical affairs HQ medical affairs Medical Science Liaison career advice

The Value of In-House Medical Affairs to the MSL E205 • May 14, 2024 • 29 mins


Share This Article


Summary

Erlene Seymour, Medical Director, US Medical Affairs Hematology at BeiGene discusses the value of In House or HQ Medical Affairs to the MSL.

Learn more about…

👉 Why is it important for MSLs to know about their inhouse counterparts and what comes from their support
👉 What makes in house medical affairs so valuable to MSLs and to the organization
👉 Advice for MSLs in how they should view and interact with their inhouse counterparts
👉 Advice for MSLs that may want to pursue a role in house or HQ medical affairs position
👉 What is it that helps MSLs stand out and separate themselves from the others

Click for Source
MSLs, in-house medical affairs, HQ medical affairs, Medical Science Liaison, career advice

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
The Four Employment Agreement Questions Every Pharma Executive Must Ask
Partner Avatar Michael Pietrack

The Four Employment Agreement Questions Every Pharma Executive Must Ask

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Value assessment of oncology drugs using a weighted criterion-based approach
OVN Avatar Doreen A. Ezeife MD, Francois Dionne PhD, Aline Fusco Fares MD, Ellen Laura Rose Cusano MD, Rouhi Fazelzad BSc, MISt, Wenzie Ng BSc, MPharm, RPh, Don Husereau BSc Pharm, MSc, Farzad Ali BPharm, MSc, Christina Sit MSc, Barry Stein B.Com BCL, LLB, Jennifer

Value assessment of oncology drugs using a weighted criterion-based approach

Article
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects
OVN Avatar Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal

Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects

Article
Outcome measures for oncology alternative payment models: practical considerations and recommendations
OVN Avatar Jakub P. Hlávka, PhD, Pei-Jung Lin, PhD, Peter J. Neumann, ScD

Outcome measures for oncology alternative payment models: practical considerations and recommendations

Explore OVN